AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 191 min read$TVTX

Dube Eric M sold $13.1M of TVTX

Dube Eric M (CHIEF EXECUTIVE OFFICER) sold 243,735 shares of Travere Therapeutics, Inc. (TVTX) at an average of $53.82 ($52.97–$55.02, $13.12M total) across 3 trades on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Dube Eric M
Published Oct 19, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TVTX
Bearish
high confidence
Mentioned
$TVTX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TVTXBearishMed
01

Why it matters

The CEO's sizable share sale may trigger short-term sell pressure, especially in a low-float biotech.

02

Market read

Insider sell signals potential downside risk for TVTX; traders may consider short positions or reduced exposure.

03

What to watch

Potential upcoming clinical trial data or financing needs that prompted the planned sale.

Relevance 6/10Novelty 7/10Timing: post-market today

Background

Form 4 filing discloses insider transactions, providing transparent insight into executive holdings.

Company-level read

Ticker impact

$TVTXBearishHigh confidence
Context

CEO Eric Dube sold 243,735 shares for $13.1M via a 10b5-1 plan, reducing his stake to 432,886 shares.

Expected impact

likely downward pressure as the market prices in the insider sale

Evidence & confidence

The sale size ($13M) is material for a small-cap biotech and was executed through a pre-arranged plan, suggesting a neutral to bearish impact.

Market effects

Sector

May weigh on other small-cap biotech stocks as investors reassess insider confidence.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

The sale could be purely liquidity-driven under a 10b5-1 plan, not reflecting company fundamentals.

Key entities

  • Company
    Travere Therapeutics, Inc.

    Biopharmaceutical company developing treatments for rare diseases.

  • Executive
    Eric Dube

    Chief Executive Officer of Travere Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TVTX insider trading history →

Related articles

OCT 23
$TVTXHighAI 8/10

At week 110, one kidney drug lowered an inflammation marker 45.4%; another raised it 8.7%.

Travere Therapeutics (TVTX) presented Phase 3 PROTECT Study data showing FILSPARI (sparsentan) reduced kidney inflammation biomarkers more than irbesartan in IgA nephropathy patients. At Week 110, FILSPARI decreased sCD163 (60.1%), BAFF (64.4%), C5b-9 (50.2%), and IL-6 (45.4%) compared to irbesartan. The study involved 404 patients, with 295 analyzed for biomarkers.

stocktitan.net2 min
SEP 30
$TVTXMed

Travere Therapeutics (TVTX) Secures FILSPARI Patent Extension, Is The Stock A Bargain?

Travere Therapeutics (TVTX) received a patent extension for FILSPARI, protecting its use in focal segmental glomerulosclerosis until October 2037. The company's stock has shown mixed performance, down 9.49% over 30 days but up 51.80% year-to-date. Analysts debate its valuation, with some seeing it as 19% undervalued at $59.99, while others note its higher P/S ratio compared to peers.

simplywall.st2 min